Form 4: Guardant Health CTO Reports Routine Stock Vesting and Tax Withholding
Insider Transaction Report
Guardant Health's Chief Technology Officer, Darya Chudova, reported the vesting of Restricted Stock Units and the subsequent sale of shares to cover tax obligations.
Summary
- Darya Chudova, Chief Technology Officer of Guardant Health, Inc., reported the vesting of 3,007 Restricted Stock Units (RSUs) on July 1, 2025. These shares were acquired at a price of $0.
- Concurrently, 1,525 shares were disposed of at a price of $50.71 to cover tax withholding obligations related to the RSU vesting.
- Following these transactions, Chudova directly beneficially owns 81,294 shares of common stock.
- Additionally, Chudova holds 6,696 unvested Restricted Stock Units from an award granted on November 7, 2022, and 8,337 unvested Restricted Stock Units from an award granted on December 13, 2023, totaling 15,033 unvested RSUs.
Sentiment
Score: 5
Explanation: The document reports a routine insider transaction (RSU vesting and tax withholding) which is neutral in sentiment, reflecting standard executive compensation practices.
Positives
- The vesting of Restricted Stock Units indicates the continued retention and incentivization of a key executive, Darya Chudova, aligning her interests with long-term company performance.
Negatives
- No inherently negative information was disclosed in this routine insider transaction report.
Future Outlook
This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.
Industry Context
This filing is a routine insider transaction report specific to Guardant Health, Inc. and does not provide broader industry context or trends.
Comparison to Industry Standards
- This Form 4 filing details a standard executive compensation event (RSU vesting and tax withholding) and does not contain information suitable for comparison to industry-specific operational or financial benchmarks.
Stakeholder Impact
- Shareholders may view the vesting of executive Restricted Stock Units as a positive indicator of executive retention and alignment of management interests with shareholder value.
Next Steps
- Remaining portions of the Restricted Stock Unit awards are scheduled to vest in equal quarterly installments over the next two to three years.
Key Dates
| Date | Description |
|---|---|
| 11/07/2022 | Grant date for a Restricted Stock Unit award to Darya Chudova. |
| 12/13/2023 | Grant date for a Restricted Stock Unit award to Darya Chudova. |
| 10/01/2023 | First vesting date for the Restricted Stock Unit award granted on November 7, 2022. |
| 10/01/2024 | First vesting date for the Restricted Stock Unit award granted on December 13, 2023. |
| 07/01/2025 | Transaction date for the vesting of Restricted Stock Units and subsequent tax withholding. |
| 07/02/2025 | Signature date of the reporting person's attorney-in-fact. |
Keywords
Guardant Health, GH, Form 4, insider transaction, stock ownership, RSU, restricted stock units, Darya Chudova, Chief Technology Officer, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.